Observational studyPloS one2026
Tuberculosis in advanced chronic kidney disease: An Observational Study at a Tertiary Care Center in Mexico.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of Tuberculosis (TB) in patients with chronic kidney disease (CKD) presents unique challenges, including an immunosuppressive state, altered drug pharmacokinetics, and limited access to single-drug formulations in our setting. There is a scarcity of real-world evidence on TB outcomes in this population in Latin America. Our study aimed to compare mortality, cure, and relapse rates between TB patients with ACKD and without ACKD.
methodsWe conducted an observational-analytical study of all patients aged ≥18 years with microbiologically or histologically confirmed TB between 2013 and 2024. Patients with ACKD (GFR < 30 mL/min/1.73 m² were compared against age- and sex-matched non-ACKD (GFR ≥ 30 mL/min/1.73 m²) patients. Due to differential HIV distribution, we also performed a sensitivity analysis excluding HIV-positive patients. The primary outcome was all-cause mortality at 1 year. Outcomes were compared using the Chi-squared and Mann-Whitney U tests, as well as logistic regression.
resultsA total of 51 patients with tuberculosis were included (17 with ACKD, 34 without ACKD). CKD was caused by lupus or diabetes in 29% of patients each. Most CKD patients (68%) received a local pragmatic alternating regimen. One-year all-cause mortality was 18% in both groups (p > 0.999), and TB-related mortality was 9% in the control group, vs 0% in the ACKD group. The cure rate was similar between groups (ACKD: 88% vs. non-ACKD: 82%; p = 0.586). No relapses occurred. In a sensitivity analysis excluding HIV-positive patients (n = 44), findings were consistent with the primary analysis, with no significant difference in mortality between groups. Due to the low event rate, we conducted a bivariate analysis in an exploratory fashion and did not perform a multivariate analysis.
conclusionsIn this Mexican small cohort, ACKD didn't significantly worsen TB outcomes compared with non-ACKD patients. An local pragmatic alternating regimen was used without apparent harm. These preliminary findings are limited by small sample size, limited statistical power, and lack of pharmacokinetic validation. Larger studies with drug monitoring are needed to optimize treatment for this vulnerable group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.